Y-mAbs to Participate in Upcoming Investor Conferences in August
Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company specializing in novel radioimmunotherapy and antibody-based cancer treatments, has announced its participation in two upcoming investor conferences in August 2024:
1. Wedbush PacGrow Healthcare Conference on August 13 in New York, NY, featuring investor 1x1 meetings.
2. Canaccord Genuity 44th Annual Growth Conference on August 14 in Boston, MA, including a fireside chat at 8:00 a.m. ET and investor 1x1 meetings.
A live webcast of Y-mAbs' fireside chat and related materials will be available on the company's investor relations website. The webcast will be archived for at least 30 days.
Y-mAbs Therapeutics (Nasdaq: YMAB), un'azienda biofarmaceutica in fase commerciale specializzata in nuove radioimmunoterapie e trattamenti antitumorali basati su anticorpi, ha annunciato la sua partecipazione a due conferenze per investitori in programma per agosto 2024:
1. Conferenza Wedbush PacGrow Healthcare il 13 agosto a New York, NY, con incontri 1x1 tra investitori.
2. 44ª Conferenza Annuale sulla Crescita di Canaccord Genuity il 14 agosto a Boston, MA, che includerà un incontro informale alle 8:00 a.m. ET e incontri 1x1 tra investitori.
Una trasmissione in diretta della chiacchierata informale di Y-mAbs e dei materiali correlati sarà disponibile sul sito web delle relazioni con gli investitori della società. La trasmissione sarà archiviata per almeno 30 giorni.
Y-mAbs Therapeutics (Nasdaq: YMAB), una empresa biofarmacéutica en etapa comercial que se especializa en nuevas radioinmunoterapias y tratamientos contra el cáncer basados en anticuerpos, ha anunciado su participación en dos conferencias para inversores que se llevarán a cabo en agosto de 2024:
1. Conferencia de Salud Wedbush PacGrow el 13 de agosto en Nueva York, NY, con reuniones 1x1 entre inversores.
2. 44ª Conferencia Anual de Crecimiento de Canaccord Genuity el 14 de agosto en Boston, MA, que incluirá un chat informal a las 8:00 a.m. ET y reuniones 1x1 entre inversores.
Una transmisión en vivo del chat informal de Y-mAbs y los materiales relacionados estará disponible en el sitio web de relaciones con los inversores de la empresa. La transmisión se archivará durante al menos 30 días.
Y-mAbs Therapeutics (Nasdaq: YMAB)는 새로운 방사면역요법 및 항체 기반 암 치료에 전문화된 상업 단계의 바이오 제약 회사로, 2024년 8월에 열리는 두 개의 투자자 회의에 참여할 것이라고 발표했습니다:
1. Wedbush PacGrow Healthcare Conference가 8월 13일 뉴욕, NY에서 개최되며, 투자자 간의 1대1 미팅이 있습니다.
2. Canaccord Genuity 제44회 연례 성장 회의가 8월 14일 보스턴, MA에서 진행되며, 오전 8시에 비공식적인 대화가 포함되고, 투자자 1대1 미팅이 있습니다.
Y-mAbs의 비공식 대화와 관련 자료의 라이브 웹캐스트가 회사의 투자자 관계 웹사이트에서 제공될 예정입니다. 웹캐스트는 최소 30일 동안 보관됩니다.
Y-mAbs Therapeutics (Nasdaq: YMAB), une entreprise bio-pharmaceutique en phase commerciale spécialisée dans les nouvelles radio-immunothérapies et les traitements anticancéreux basés sur des anticorps, a annoncé sa participation à deux conférences pour investisseurs prévues en août 2024 :
1. Conférence Wedbush PacGrow Healthcare le 13 août à New York, NY, avec des réunions 1x1 entre investisseurs.
2. 44e Conférence Annuelle sur la Croissance de Canaccord Genuity le 14 août à Boston, MA, incluant une discussion informelle à 8h00 ET et des réunions 1x1 entre investisseurs.
Un webinaire en direct de la discussion informelle de Y-mAbs et des documents connexes sera disponible sur le site web des relations investisseurs de l’entreprise. Le webinaire sera archivé pendant au moins 30 jours.
Y-mAbs Therapeutics (Nasdaq: YMAB), ein Unternehmen der Biopharmaindustrie in der kommerziellen Phase, das sich auf neuartige Radioimmuntherapien und antikörperbasierte Krebsbehandlungen spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im August 2024 angekündigt:
1. Wedbush PacGrow Healthcare Conference am 13. August in New York, NY, mit 1x1 Treffen von Investoren.
2. 44. Jahreskonferenz für Wachstum von Canaccord Genuity am 14. August in Boston, MA, einschließlich eines informellen Gesprächs um 8:00 Uhr ET und 1x1 Treffen von Investoren.
Ein Live-Webcast des informellen Gesprächs von Y-mAbs und zugehöriger Materialien wird auf der Webseite der Unternehmensinvestorenbeziehungen verfügbar sein. Der Webcast wird mindestens 30 Tage lang archiviert.
- None.
- None.
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced its management team will participate in the following upcoming investor conferences:
Wedbush PacGrow Healthcare Conference
Date: Tuesday, August 13, 2024
Location: New York, NY
Format: Investor 1x1 meetings
Canaccord Genuity 44th Annual Growth Conference
Date: Wednesday, August 14, 2024
Time: 8:00 a.m. ET
Location: Boston, MA
Format: Fireside chat and investor 1x1 meetings
A live webcast of Y-mAbs’ fireside chat and any accompanying materials will be available under the Presentations section of the Company’s investor relations website at ir.ymabs.com. The webcast will be archived for at least 30 days.
About Y-mAbs
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT”) and bispecific antibodies generated using the Y-BiClone platform. The Company’s broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, statements about our business model, including financial outlook for 2024 and beyond, including estimated operating expenses, cash burn and DANYELZA product revenue and sufficiency of cash resources and related assumptions; implied and express statements regarding the future of the Company’s business, including with respect to expansion and its goals; the Company’s plans and strategies, development, commercialization and product distribution plans; expectations with respect to the Company’s products and product candidates, including potential territory and label expansion of DANYELZA and the potential market opportunity related thereto and potential benefits thereof, and the potential of the SADA PRIT Technology and potential benefits and applications thereof; the Company’s mission of delivering better and safer therapies to patients; expectations relating to key anticipated development milestones, including potential expansion and advancement of commercialization and development efforts, including potential indications, applications and geographies, and the timing thereof; expectations with respect to current and future clinical and pre-clinical studies and the Company’s research and development programs, including with respect to timing and results; expectations related to the timing of the initiation and completion of regulatory submissions; additional product candidates and technologies; expectations regarding collaborations or strategic partnerships and the potential benefits thereof; expectations related to the use of cash and cash equivalents, and the need for, timing and amount of any future financing transaction; expectations with respect to the Company’s future financial performance; and other statements that are not historical facts. Words such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will,” ‘‘would’,’ “guidance,” “goal,” “objective,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company’s financial condition and need for additional capital; the risks that actual results of the Company’s restructuring plan and revised business plan will not be as expected; risks associated with the Company’s development work; cost and success of the Company’s product development activities and clinical trials; the risks of delay in the timing of the Company’s regulatory submissions or failure to receive approval of its drug candidates; the risks related to commercializing any approved pharmaceutical product including the rate and degree of market acceptance of product candidates; development of sales and marketing capabilities and risks associated with failure to obtain sufficient reimbursement for products; the risks related to the Company’s dependence on third parties including for conduct of clinical testing and product manufacture; the Company’s ability to enter into partnerships; the risks related to government regulation; risks related to market approval, risks associated with protection of the Company’s intellectual property rights; risks related to employee matters and managing growth; risks related to the Company’s common stock, risks associated with macroeconomic conditions, including the conflict between Russia and Ukraine and sanctions related thereto, the state of war between Israel and Hamas and the related risk of a larger regional conflict, inflation, increased interest rates, uncertain global credit and capital markets and disruptions in banking systems; and other risks and uncertainties affecting the Company including those described in the "Risk Factors" section included in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, and future filings and reports by the Company. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
DANYELZA® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutics, Inc.
Investor Contact:
Courtney Dugan
VP, Head of Investor Relations
cdu@ymabs.com
FAQ
What investor conferences will Y-mAbs Therapeutics (YMAB) attend in August 2024?
When and where will Y-mAbs Therapeutics (YMAB) present at the Canaccord Genuity conference?
How can investors access Y-mAbs Therapeutics' (YMAB) presentation at the Canaccord Genuity conference?
What type of meetings will Y-mAbs Therapeutics (YMAB) conduct at the Wedbush PacGrow Healthcare Conference?
How long will the webcast of Y-mAbs Therapeutics' (YMAB) presentation be available?
